Cargando…

Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study

OBJECTIVE: To determine the effect of age and gender on persistence and adherence in patients taking dabigatran for atrial fibrillation. DESIGN: A retrospective observational study over 4 years using refill prescription data from the National Pharmaceutical Database. SETTING: All patients in New Zea...

Descripción completa

Detalles Bibliográficos
Autores principales: Harper, Paul, Pollock, Daryl, Stephens, Matt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892768/
https://www.ncbi.nlm.nih.gov/pubmed/29626048
http://dx.doi.org/10.1136/bmjopen-2017-020212
_version_ 1783313212142256128
author Harper, Paul
Pollock, Daryl
Stephens, Matt
author_facet Harper, Paul
Pollock, Daryl
Stephens, Matt
author_sort Harper, Paul
collection PubMed
description OBJECTIVE: To determine the effect of age and gender on persistence and adherence in patients taking dabigatran for atrial fibrillation. DESIGN: A retrospective observational study over 4 years using refill prescription data from the National Pharmaceutical Database. SETTING: All patients in New Zealand who received dabigatran from July 2011 to September 2015. POPULATION: 43 339 people filled at least one prescription of dabigatran. MAIN OUTCOME MEASURES: The proportion of patients with good adherence (treatment available at least 80% of the time), and the proportion at risk of thrombosis (a break in treatment of more than 2 days) measured 6-monthly for 3 years. Medication persistence recorded over 3 years. RESULTS: Persistence was highest in older patients and showed a significant correlation with age (p<0.001); 24% over 70 years had discontinued treatment by 6 months compared with 50% under 50 years. Adherence was highest in the elderly (p<0.001) with 90% of patients over 80 years with good adherence at 12 months compared with 70% in patients aged 50–60 years and less than 60% in those under 50 years. The time at risk of thrombosis showed a similar pattern with 25% below 60 years with inadequate anticoagulation more than 20% of the time. Adherence dropped during the first 18 months of treatment with the most marked fall in those under 50 years. Adherence shows that breaks in treatment are common with 30% of men under 60 years with a break in treatment of at least 28 days during the first 12 months. CONCLUSION: Adherence and persistence correlate with the patient’s age. Those over 70 years have high adherence consistent over time whereas younger patients have significantly worse adherence which declines over the first 18 months, with the lowest rate in those under 50 years. Adherence in our study is lower than reported in clinical trials, therefore the benefit of dabigatran in stroke prevention may not be realised in clinical practice especially in younger patients.
format Online
Article
Text
id pubmed-5892768
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-58927682018-04-13 Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study Harper, Paul Pollock, Daryl Stephens, Matt BMJ Open Haematology (Incl Blood Transfusion) OBJECTIVE: To determine the effect of age and gender on persistence and adherence in patients taking dabigatran for atrial fibrillation. DESIGN: A retrospective observational study over 4 years using refill prescription data from the National Pharmaceutical Database. SETTING: All patients in New Zealand who received dabigatran from July 2011 to September 2015. POPULATION: 43 339 people filled at least one prescription of dabigatran. MAIN OUTCOME MEASURES: The proportion of patients with good adherence (treatment available at least 80% of the time), and the proportion at risk of thrombosis (a break in treatment of more than 2 days) measured 6-monthly for 3 years. Medication persistence recorded over 3 years. RESULTS: Persistence was highest in older patients and showed a significant correlation with age (p<0.001); 24% over 70 years had discontinued treatment by 6 months compared with 50% under 50 years. Adherence was highest in the elderly (p<0.001) with 90% of patients over 80 years with good adherence at 12 months compared with 70% in patients aged 50–60 years and less than 60% in those under 50 years. The time at risk of thrombosis showed a similar pattern with 25% below 60 years with inadequate anticoagulation more than 20% of the time. Adherence dropped during the first 18 months of treatment with the most marked fall in those under 50 years. Adherence shows that breaks in treatment are common with 30% of men under 60 years with a break in treatment of at least 28 days during the first 12 months. CONCLUSION: Adherence and persistence correlate with the patient’s age. Those over 70 years have high adherence consistent over time whereas younger patients have significantly worse adherence which declines over the first 18 months, with the lowest rate in those under 50 years. Adherence in our study is lower than reported in clinical trials, therefore the benefit of dabigatran in stroke prevention may not be realised in clinical practice especially in younger patients. BMJ Publishing Group 2018-04-05 /pmc/articles/PMC5892768/ /pubmed/29626048 http://dx.doi.org/10.1136/bmjopen-2017-020212 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Haematology (Incl Blood Transfusion)
Harper, Paul
Pollock, Daryl
Stephens, Matt
Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study
title Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study
title_full Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study
title_fullStr Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study
title_full_unstemmed Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study
title_short Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study
title_sort dabigatran persistence and adherence in new zealand: a nationwide retrospective observational study
topic Haematology (Incl Blood Transfusion)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892768/
https://www.ncbi.nlm.nih.gov/pubmed/29626048
http://dx.doi.org/10.1136/bmjopen-2017-020212
work_keys_str_mv AT harperpaul dabigatranpersistenceandadherenceinnewzealandanationwideretrospectiveobservationalstudy
AT pollockdaryl dabigatranpersistenceandadherenceinnewzealandanationwideretrospectiveobservationalstudy
AT stephensmatt dabigatranpersistenceandadherenceinnewzealandanationwideretrospectiveobservationalstudy